Novo Nordisk A S vs Takeda Pharmaceutical
NVO and TAK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NVO and TAK compare
Novo Nordisk A S grew revenue faster over the last twelve months (6.4% versus −1.7% for Takeda Pharmaceutical).
Takeda Pharmaceutical scores higher on the StockData Score (5 against 4 for Novo Nordisk A S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NVO | TAK |
|---|---|---|
| Size and price | ||
| Share price | $40.00 | $20.91 |
| Change, 1 year | −22.1% | 51.9% |
| Change, 5 years | −29.5% | 46.7% |
| Beta (5Y) | 0.76 | 0.22 |
| Employees | 70K | 47K |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 6.4% (better) | −1.7% |
| Revenue growth, 5Y average | 19.5% (better) | 7.1% |
| Net income growth (TTM) | – | −241% |
| EPS growth (TTM) | 1.8% (better) | −244% |
| EPS growth, 5Y average | 20.7% | – |
| Profitability | ||
| Gross margin | 81.0% (better) | 65.1% |
| Operating margin | 41.3% (better) | 0.14% |
| Net margin | – | −3.4% |
| FCF margin | 19.1% | 19.2% (better) |
| Return on equity | – | −2.1% |
| Return on invested capital | – | 0.04% |
| Financial health | ||
| Debt / equity | – | 0.66 |
| Net debt / EBITDA | 0.82 (better) | 5.89 |
| Interest coverage | 18.8× (better) | 0.0× |
| Current ratio | 0.80 | 1.09 (better) |
| Piotroski F-score | – | 5 |
| Ownership | ||
| Held by institutions | 7.3% | 6.0% |
| Held by insiders | 0.00% | 0.22% |
| Insider net buying, 12 months | – | −$13.1M |
| Superinvestors holding | 1 | – |
Go deeper
- NVO stock overview
- NVO income statement
- NVO valuation and score
- TAK stock overview
- TAK income statement
- TAK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.